Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Futura MedicalFAMDF -73.00% 3-Year FCF Growth Rate is 9.60% as of Dec. 2025, which is 153% above its 10-year median of 3.80. The stock has 5 warning signs investors should review. Among 1,111 Biotechnology companies, Futura Medical ranks worse than 62.74% on this metric.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 9.60% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 17.50% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 18.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Futura Medical was 46.00% per year. The lowest was -31.00% per year. And the median was 3.80% per year.
Futura Medical (OTCPK:FAMDF) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Futura Medical 3-Year FCF Growth Rate Related Terms
FAMDF vs VRTX, REGN, RVMD: 3-Year FCF Growth Rate Comparison
For the Biotechnology subindustry, Futura Medical's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Futura Medical 3-Year FCF Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Futura Medical's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Futura Medical's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Futura Medical (FAMDF) has a 3-Year FCF Growth Rate of 9.60% as of Dec. 2025. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Futura Medical and its competitors. This is 153% above median its historical median of 3.80. According to the industry distribution chart, Futura Medical ranks #697 out of 1111 companies in the Biotechnology industry, placing it in the top 62.7%.
Is Futura Medical's 3-Year FCF Growth Rate too high?
Futura Medical's current 3-Year FCF Growth Rate of 9.60% is 153% above median its 10-year median of 3.80. The Biotechnology industry median 3-Year FCF Growth Rate is 19.20. Futura Medical's value of 9.60% is 50% below this industry median. Based on the distribution chart, Futura Medical ranks #697 out of 1111 companies in the Biotechnology industry, which is below the industry midpoint.
How does Futura Medical's 3-Year FCF Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Futura Medical ranks #697 out of 1111 companies for 3-Year FCF Growth Rate. This places Futura Medical in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 19.20. Futura Medical's value of 9.60% is 50% below this benchmark. While the company's 10-year median is 3.80 vs. the industry median of 19.20, Futura Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Biotechnology company?
The median 3-Year FCF Growth Rate among Biotechnology companies is 19.20, based on 1,111 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Futura Medical's current 3-Year FCF Growth Rate of 9.60% is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Futura Medical and its competitors. For the Biotechnology industry, the median 3-Year FCF Growth Rate is 19.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Futura Medical's current 3-Year FCF Growth Rate is 9.60%, which is 153% above median its own 10-year median of 3.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Futura Medical stock overvalued right now?
Based on GuruFocus' analysis, Futura Medical (FAMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.00 — trading 96.6% below its estimated fair value. The current 3-Year FCF Growth Rate is 9.60%, which is 153% above median its 10-year median of 3.80 and 50% below the Biotechnology industry median of 19.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Futura Medical (FAMDF), the current 3-Year FCF Growth Rate is 9.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Futura Medical PLC is engaged in the development and commercialization of sexual health products. Its product Eroxon is a treatment for erectile dysfunction. Geographically, the company derives the majority of its revenue from the United Kingdom and the European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FAMDF has been successfully added to your 
